Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers

Schizophrenia Clinical Trial

Official title:

An Open Label Positron Emission Tomography (PET) Study to Evaluate Dopamine Receptor Occupancy of LB-102 Administered Orally to Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04588129
• Other study ID #: LB-102-002
• Status: Completed
• Phase: Phase 1
• Start date: January 5, 2021
• Est. completion date: November 15, 2021

Study information

• Verified date: April 2022
• Source: LB Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open label study in 4 cohort of 4 healthy volunteers each designed to evaluate the dopamine receptor occupancy of LB-102 at various doses and timepoints.

Description:

This is a Phase 1, open label study designed to evaluate the dopamine receptor occupancy in healthy subjects. There will be 4 cohorts consisting of 4 subjects each. Eligible subjects will receive 1 or 2 doses of LB-102 on Day 1: subjects in the final cohort will be dosed for 5 days BID (ie twice/day) on an inpatient basis. This will be an open label study. Blood samples for pharmacokinetic (PK) and safety assessments will be collected at screening, immediately pre-dose, and during/before/after PET scan. Subjects enrolled in the inpatient cohort will be monitored daily. Follow-up after discharge will consist of a phone call the evening of discharge and the next day to check on subjects. This will be an adaptive study and doses in cohorts 2-4 will be determined after PET data from Cohort 1 are obtained.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: November 15, 2021
• Est. primary completion date: September 17, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

Body Mass Index (BMI) = 18 and = 30 kg/m2 at screening visit. Competent to provide informed consent. Subjects must be in good general health as determined by medical history and physical examination with no clinically significant medical findings and no history of significant medical disease (e.g., cardiovascular, pulmonary, renal, etc.) or acute condition with the past 30 days, as determined by the study investigators. Have normal clinical laboratory test results and ECG, which are not considered to be clinically significant by the Investigator.

Exclusion Criteria:

1. Are pregnant or lactating.

2. Have a history or presence of significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological or psychological/psychiatric disorders which, in the opinion of the Investigator, increases the risk of the study drug or may confound the interpretation of study measures.

3. Clinically significant abnormal findings on physical examination or vital signs as determined by Investigator.

4. Individuals with pacemakers, aneurysm clips, shrapnel, or other restricted implanted metallic devices will be excluded from study. All subjects complete the standard MRI screening questionnaire prior to MRI.

5. History or presence of psychiatric or neurological disease or condition, as determined by the Investigator.

6. History of seizures.

7. Subject with any history or current evidence of suicidal behavior.

8. Unwilling to complete any planned study assessments.

9. Have a history of blood donation in excess of 500 mL of blood within 30 days prior to Screening.

10. Have received treatment with an investigational drug or device within 30 days prior to Screening.

11. Have a positive test for Human Immunodeficiency Virus (HIV) antibodies 1 and 2, Hepatitis B Surface Antigen (HBsAg) or Hepatitis C Virus (HCV) antibody.

12. Any subject who is known to be allergic to the study drug or any components of the study drug.

13. The subject has a fasting blood glucose = 126 mg/dL or hemoglobin A1c (HbA1c) = 6.5% at Screening.

14. The subject has a history of QT prolongation or dysrhythmia or a family history of prolonged QT interval or sudden death.

15. Clinically significant abnormal finding on ECG (electrocardiogram) and/or evidence of

any of the following cardiac conduction abnormalities at Screening:

1. Heart rate < 40 bpm and > 100 bpm (based on the ECG reading)

2. QTcF interval > 450 msec for males and females

3. PR interval = 200 msec

4. Intraventricular conduction delay with QRS duration > 120 msec

5. Evidence of second- or third-degree atrioventricular block (AVB)

6. Electrocardiographic evidence of complete left bundle branch block (LBBB), complete right bundle branch block (RBBB), or incomplete LBBB

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Drug:
• LB-102
(N-Methyl amisulpride)

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (2)

Lead Sponsor	Collaborator
LB Pharmaceuticals Inc.	Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Brain Receptor Occupancy as Measured by Positron Emission Tomography	PET scan of D2/D3 receptor occupancy using raclopride as a tracer	2.5 hours post LB-102 dose
Primary	Brain Receptor Occupancy as Measured by Positron Emission Tomography	PET scan of D2/D3 receptor occupancy using raclopride as a tracer	7.5 hours post LB-102 dose
Primary	Brain Receptor Occupancy as Measured by Positron Emission Tomography	PET scan of D2/D3 receptor occupancy using raclopride as a tracer	23.5 hours post LB-102 dose
Secondary	Safety and Tolerability as Measured by Reported Adverse Events	Measurement of clinical events as determined by medical staff reporting	Up to 14 days

External Links

•   Corporate Website